ClinicalTrials.gg
CompletedNCT07790757Updated Aug 27, 2026

Efficacy of Topical Insulin Gel as a Coupling Medium in Phonophoresis-Assisted Physiotherapy vs Liposomal Insulin in Management of Joint Inflammation

A Phase 1 interventional study of Insulin and nano-insulin gel in Joint Inflammation, sponsored by Deraya University. Completed at 1 site in Egypt. Open to participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Deraya University · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Study summary

Although most clinical applications of topical insulin have centered on diabetic wound healing, emerging evidence in animal models supports its use in musculoskeletal inflammation. In osteoarthritic models, insulin was shown to downregulate cartilage-degrading enzymes (MMP-1, MMP-13, ADAMTS4) in synovial fibroblasts by activating the insulin receptor and PI3K/Akt signaling pathways, indicating direct synovial anti-inflammatory effects3.

From a physiotherapeutic perspective, therapeutic ultrasound facilitates deeper tissue heating and enhances local circulation, potentially improving the dermal and transdermal absorption of topically applied agents. Therefore, using insulin in gel form as a coupling medium offers dual benefits: enhanced drug delivery via ultrasound and localized modulation of inflammatory processes in joints and soft tissues. This synergy could lead to superior pain relief and functional recovery compared to standard ultrasound gel.

  • Primary Objective: To evaluate the effect of topical nano-insulin gel on pain reduction and functional improvement compared to standard insulin gel combined with the Phonophoresis technique.
  • Secondary Objectives: To assess quality of life markers as changes in joint mobility, strength, and incidence of local/systemic adverse effects.
02

Conditions studied

  • Joint Inflammation

Browse trials for

03

In context

Arthritis

843 studies on the registry are indexed under Arthritis; 118 are open to participants now.

This study's enrollment of 60 is below the median of 97 across 599 interventional studies indexed under Arthritis.

Browse Arthritis studies →

Lead sponsor

Deraya University is the lead sponsor of 50 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 40 Years to 60 Years (Adult )
  • Patient with diagnosis of shoulder soft tissue inflammation due to SAIS/
  • Unilateral or bilateral grade II shoulder osteoarthritis (clinical and imaging diagnosis X-ray).
  • Patient suffering from shoulder soft tissue inflammation due to SAIS/RCT pain for more than 3 months before enrollment

Exclusion criteria

Exclusion Criteria:

  • Known diabetes mellitus (Type 1 or uncontrolled Type 2)
  • Skin conditions or open wounds at application site
  • to insulin or gel components
  • Use of or NSAIDs within 1 week before enrollment Anterior Cruciate Ligament (ACL) and meniscus injury
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Insulin gel group

    Drug: Insulin

  • Experimental
    Insulin liposomes group

    Drug: nano-insulin gel

  • Placebo comparator
    phonophoresis only group

    Radiation: phonophoresis and ultasound

Interventions

  • Topical insulin gel (2 IU/g) applied with phonophoresis technique

  • Drugnano-insulin gel

    Transferosomes were formulated by the conventional handshaking method using Phos-pholipid (soylecithin) and surfactant (sodium deoxycholate) are mixed with chloroform in the ratio 1:1:1

  • Radiationphonophoresis and ultasound

    combination of ultrasound and phonophoresis without insulin

06

What researchers measure

Primary outcomes

  1. Pain scoring 0-10

    The visual analog scale (VAS) is a pain rating scale first used. Scores are based on self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm).

    Time frame: at 4 an 8 week

  2. Functional Status

    Shoulder/Upper Limb: DASH Questionnaire, Shoulder pain and disability measured with the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire (the score output is given as a percentage -from 0% to 100%- and the lower the percentage the better is the clinical outcome, the higher the percentage the worse is the clinical outcome) performed at 2, 4, 6 and at 12 weeks after treatment start compared to baseline.

    Time frame: at 4 and 8 week

07

Study locations

1 site
  • Deraya university, physiotherapy clinics
    Minya, 05673, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Nov 2025, 4 months.

Of 14 phase 1 interventional studies under Arthritis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2025
First posted
Aug 27, 2026
StartActual
Jul 1, 2025
Primary completionActual
Nov 1, 2025
CompletionActual
Feb 1, 2026
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07790757
Lead sponsor
Deraya University
Responsible party
Sponsor
First posted
Aug 27, 2026
Start date
Jul 1, 2025
Primary completion
Nov 1, 2025
Completion
Feb 1, 2026
Last update
Aug 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion